Literature DB >> 11003603

Expression and regulation of parathyroid hormone-related peptide in normal and malignant melanocytes.

K El Abdaimi1, V Papavasiliou, D Goltzman, R Kremer.   

Abstract

We examined parathyroid hormone-related peptide (PTHrP) production and regulation in both normal human melanocytes and in a human amelanotic melanoma cell line (A375). Northern blot and immunocytochemical analysis demonstrated that both cultured A375 cells and normal human melanocytes express PTHrP, but A375 cells expressed much higher levels of the peptide. PTHrP secretory rate increased at least 10-fold after treatment with 10% fetal bovine serum (100.2 +/- 2.8 pmol/10(6) cells vs. basal <15 pmol/10(6) cells) in proliferating A375 cells but only twofold in confluent cells. Treatment of A375 cells with increasing concentrations of 1, 25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] or its low-calcemic analog EB-1089 revealed that EB-1089 was 10-fold more potent than 1, 25-(OH)(2)D(3) on inhibition of both cell proliferation and PTHrP expression. Furthermore, inoculation of A375 cells into the mammary fat pad of female severe combined immunodeficiency mice resulted in the development of hypercalcemia and elevated concentrations of plasma immunoreactive PTHrP in the absence of detectable skeletal metastases. Our study, therefore, demonstrates a stepwise increase in PTHrP expression when cells progress from normal to malignant phenotype and suggests that EB-1089 should be further evaluated as a therapeutic agent in human melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11003603     DOI: 10.1152/ajpcell.2000.279.4.C1230

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  7 in total

1.  PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target.

Authors:  Jiarong Li; Andrew C Karaplis; Dao C Huang; Peter M Siegel; Anne Camirand; Xian Fang Yang; William J Muller; Richard Kremer
Journal:  J Clin Invest       Date:  2011-11-07       Impact factor: 14.808

2.  Serum calcium, albumin and tumor stage in cutaneous malignant melanoma.

Authors:  Mridul Datta; Paul Savage; James Lovato; Gary G Schwartz
Journal:  Future Oncol       Date:  2016-06-16       Impact factor: 3.404

3.  Parathyroid Hormone-Related Peptide-Linked Hypercalcemia in a Melanoma Patient Treated With Ipilimumab: Hormone Source and Clinical and Metabolic Correlates.

Authors:  Teresa Anne Mills; Marlana Orloff; Marina Domingo-Vidal; Paolo Cotzia; Ruth C Birbe; Rossitza Draganova-Tacheva; Maria P Martinez Cantarin; Madalina Tuluc; Ubaldo Martinez-Outschoorn
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

4.  Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody.

Authors:  Anne Camirand; Ibtihal Fadhil; Aimée-Lee Luco; Benoît Ochietti; Richard B Kremer
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

5.  Cancer Diagnostics via Ultrasensitive Multiplexed Detection of Parathyroid Hormone-Related Peptides with a Microfluidic Immunoarray.

Authors:  Brunah A Otieno; Colleen E Krause; Abby L Jones; Richard B Kremer; James F Rusling
Journal:  Anal Chem       Date:  2016-09-08       Impact factor: 6.986

Review 6.  Animal Models of Cancer-Associated Hypercalcemia.

Authors:  Nicole A Kohart; Said M Elshafae; Justin T Breitbach; Thomas J Rosol
Journal:  Vet Sci       Date:  2017-04-13

7.  PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease.

Authors:  Gloria Assaker; Anne Camirand; Bassam Abdulkarim; Atilla Omeroglu; Jean Deschenes; Kurian Joseph; Abu Shadat Mohammod Noman; Agnihotram V Ramana Kumar; Richard Kremer; Siham Sabri
Journal:  JNCI Cancer Spectr       Date:  2019-08-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.